Market Research Report
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025
|Published by||Kalorama Information||Product code||299928|
|Published||Content info||340 Pages
Delivery time: 1-2 business days
|Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025|
|Published: July 27, 2016||Content info: 340 Pages||
The pharmaceutical market has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 examines the leaders in the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts based recent market conditions. For each company covered, the report provides:
The companies included in the study are:
Despite the new approaches, new technologies and a wealth of new information, drug R&D is still challenged by understanding exactly how drugs will work and why they may fail. Target validation remains a quandary as well. Thus, the hurdle of getting past Phase III trials and launching more NMEs continues. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 provides a thorough discussion of current trends in pharmaceutical research and development, including:
The report also looks at market trends and values by therapeutic area, providing information on the following segments:
In addition to its company focus, the report examines the global pharmaceutical market, which has continued its recovery from the economic downfall experienced in recent years. Healthcare costs as a percent of GDP are increasing in almost all countries, though there are some exceptions. There are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. Data provided include:
For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical, including biopharmaceutical products. The market excludes consumer pharmaceuticals, diagnostics, devices, chemicals, agriculture and animal health. These are areas where many of these companies also compete with significant market shares.
Also, despite an in-depth interview process and complete review of company financials and literature, some variation in company rankings is possible. This is more likely with privately held companies or companies where prescription pharmaceutical sales are not discussed.
This report provides long-term company sales forecasts, which are based on 2015 market conditions. Company forecasts were derived from a combination of pipeline analyses, current product reviews, patent and exclusivity activities, recent merger and alliance impacts, and a number of other factors discovered throughout the writing of this report.